Background: Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019. Methods: We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects. Results: Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days. Conclusions: The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.
CITATION STYLE
Pulvirenti, F., Milito, C., Cinetto, F., Fernandez Salinas, A., Terreri, S., Piano Mortari, E., … Quinti, I. (2022). Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients with Coronavirus Disease 2019 and Primary Antibody Deficiency. Journal of Infectious Diseases, 225(5), 820–824. https://doi.org/10.1093/infdis/jiab554
Mendeley helps you to discover research relevant for your work.